

Schizophrenia

**A Trial of the Efficacy and the Safety of RO6889450 vs Placebo  
in Patients With an Acute Exacerbation of Schizophrenia or  
Schizoaffective Disorder**

**Trial Status**  
Completed

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT04512066 BP41743

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT04512066 BP41743**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 45 Years

**Healthy Volunteers**  
No

---